Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that lead to ...

Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecules that lead to major medical advances -- but it is already streamlining less ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Michael Patten, chief strategy officer of Harbour BioMed, a global biotech firm with Chinese roots that has a partnership ...

Learn how new oral GLP-1 weight loss pills work, how they compare with injections, and how the next generation of “small ...

From diagnostics to CRISPR and policy reform, explore how science and society are working together to combat the rising ...

The U.S. is taking drastic measures to end animal testing, but the move is raising questions and controversy in the medical ...

Parents of autistic children are clamoring for a prescription vitamin promoted by federal health officials. But there's ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...